P

fizer (PFE) has begun its first human trials of a gene therapy to treat Duchenne muscular dystrophy, following two other companies that have launched trials and one treatment for the disease in recent years.

The first patient received the experimental therapy, called PF-06939926, on March 22, Pfizer said Thursday. The study is expected to run through 2019 and to enroll about a dozen boys from 5 to 12 years old at four sites.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy